Cargando…

Renal Carcinoma and Angiogenesis: Therapeutic Target and Biomarkers of Response in Current Therapies

SIMPLE SUMMARY: The treatment of renal cancer is currently based on the use of antiangiogenic drugs targeting the VEGF-A pathway and/or immunotherapy targeting immune checkpoint inhibitors. Despite combined therapies being approved as first-line treatments, all patients will not benefit from them. W...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guillaume, Zoé, Auvray, Marie, Vano, Yann, Oudard, Stéphane, Helley, Dominique, Mauge, Laetitia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9776425/ https://www.ncbi.nlm.nih.gov/pubmed/36551652 http://dx.doi.org/10.3390/cancers14246167

Ejemplares similares

MiTF/TFE Translocation Renal Cell Carcinomas: From Clinical Entities to Molecular Insights
por: Simonaggio, Audrey, et al.
Publicado: (2022)

Control of the Adaptive Immune Response by Tumor Vasculature
por: Mauge, Laetitia, et al.
Publicado: (2014)

Tumor Microenvironment Features as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors (ICI) in Metastatic Clear Cell Renal Cell Carcinoma (mccRCC)
por: Simonaggio, Audrey, et al.
Publicado: (2021)

Resistance to cancer immunotherapy in metastatic renal cell carcinoma
por: Moreira, Marco, et al.
Publicado: (2020)

Imaging Response of Antiangiogenic and Immune-Oncology Drugs in Metastatic Renal Cell Carcinoma (mRCC): Current Status and Future Challenges
por: Fournier, Laure, et al.
Publicado: (2017)

Comparative Efficacy of First-Line Immune-Based Combination Therapies in Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-Analysis
por: Elaidi, Reza, et al.
Publicado: (2020)

Blood glucose levels in patients with metastatic renal cell carcinoma treated with sunitinib
por: Billemont, B, et al.
Publicado: (2008)

Enhance the Immune Checkpoint Inhibitors Efficacy with Radiotherapy Induced Immunogenic Cell Death: A Comprehensive Review and Latest Developments
por: Procureur, Adrien, et al.
Publicado: (2021)

Prognostic and theranostic impact of molecular subtypes and immune classifications in renal cell cancer (RCC) and colorectal cancer (CRC)
por: Becht, Etienne, et al.
Publicado: (2015)

Optimal cut-off for neutrophil-to-lymphocyte ratio: Fact or Fantasy? A prospective cohort study in metastatic cancer patients
por: Vano, Yann-Alexandre, et al.
Publicado: (2018)

Antiangiogenic therapy for advanced renal cell carcinoma: Management of treatment-related toxicities
por: Cohen, Roger B., et al.
Publicado: (2012)

Cabozantinib‐nivolumab sequence in metastatic renal cell carcinoma: The CABIR study
por: Vano, Yann‐Alexandre, et al.
Publicado: (2022)

Direct Oral Anticoagulants as Successful Treatment of Heparin-Induced Thrombocytopenia: A Parisian Retrospective Case Series
por: Carré, Julie, et al.
Publicado: (2021)

Molecular Classification of Renal Cell Carcinoma and Its Implication in Future Clinical Practice
por: Casuscelli, Jozefina, et al.
Publicado: (2017)

Inherited Thrombophilia in the Era of Direct Oral Anticoagulants
por: Khider, Lina, et al.
Publicado: (2022)

Soluble CD146 is a predictive marker of pejorative evolution and of sunitinib efficacy in clear cell renal cell carcinoma
por: Dufies, Maeva, et al.
Publicado: (2018)

Renal malacoplakia: Case report of a differential diagnosis for renal cell carcinoma
por: Ayllon, Jorge, et al.
Publicado: (2012)

REchallenge of NIVOlumab (RENIVO) or Nivolumab-Ipilimumab in Metastatic Renal Cell Carcinoma: An Ambispective Multicenter Study
por: Vauchier, Charles, et al.
Publicado: (2022)

Silencing of genes by promoter hypermethylation shapes tumor microenvironment and resistance to immunotherapy in clear-cell renal cell carcinomas
por: Lu, Xiaofan, et al.
Publicado: (2023)

CircRNAs as Novel Biomarkers and Therapeutic Targets in Renal Cell Carcinoma
por: Zhou, Yuxia, et al.
Publicado: (2022)

Low-Molecular-Weight Fucoidan Induces Endothelial Cell Migration via the PI3K/AKT Pathway and Modulates the Transcription of Genes Involved in Angiogenesis
por: Bouvard, Claire, et al.
Publicado: (2015)

Severe Cellular Immunodeficiency Triggered by the CDK4/6 Inhibitor Palbociclib
por: Guillaume, Zoé, et al.
Publicado: (2020)

Increased VEGFR2 expression during human late endothelial progenitor cells expansion enhances in vitro angiogenesis with up-regulation of integrin α(6)
por: Smadja, David M, et al.
Publicado: (2007)

Metastatic Renal Medullary and Collecting Duct Carcinoma in the Era of Antiangiogenic and Immune Checkpoint Inhibitors: A Multicentric Retrospective Study
por: Guillaume, Zoé, et al.
Publicado: (2022)

PD-1 as an emerging therapeutic target in renal cell carcinoma: current evidence
por: Tykodi, Scott S
Publicado: (2014)

CD248 as a bridge between angiogenesis and immunosuppression: a promising prognostic and therapeutic target for renal cell carcinoma
por: Liu, Shaojie, et al.
Publicado: (2021)

Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma
por: Motzer, Robert J, et al.
Publicado: (2022)

Carbamylated Proteins in Renal Disease: Aggravating Factors or Just Biomarkers?
por: Gorisse, Laëtitia, et al.
Publicado: (2022)

Biomarkers: the next therapeutic hurdle in metastatic renal cell carcinoma
por: Sonpavde, G, et al.
Publicado: (2012)

GSDMs are potential therapeutic targets and prognostic biomarkers in clear cell renal cell carcinoma
por: Yao, Lei, et al.
Publicado: (2022)

Freud
por: Mauge, Roger
Publicado: (1976)

Sorafenib for Older Patients With Renal Cell Carcinoma: Subset Analysis From a Randomized Trial
por: Eisen, Tim, et al.
Publicado: (2008)

Identification of Therapeutic Targets and Prognostic Biomarkers Among CXC Chemokines in the Renal Cell Carcinoma Microenvironment
por: Zeng, Qingquan, et al.
Publicado: (2020)

Bioinformatic gene analysis for possible biomarkers and therapeutic targets of hypertension-related renal cell carcinoma
por: Huang, Wenjie, et al.
Publicado: (2020)

Treprostinil increases the number and angiogenic potential of endothelial progenitor cells in children with pulmonary hypertension
por: Smadja, David M., et al.
Publicado: (2010)

Molecular Therapeutic Targets for Glioma Angiogenesis
por: Takano, Shingo, et al.
Publicado: (2010)

Possible novel targets for therapeutic angiogenesis
por: Cristofaro, Brunella, et al.
Publicado: (2009)

The expression and function of RASAL2 in renal cell carcinoma angiogenesis
por: Hui, Ke, et al.
Publicado: (2018)

Circulating Endothelial Cells in Refractory Pulmonary Hypertension in Children: Markers of Treatment Efficacy and Clinical Worsening
por: Levy, Marilyne, et al.
Publicado: (2013)

Correction: Circulating Endothelial Cells in Refractory Pulmonary Hypertension in Children: Markers of Treatment Efficacy and Clinical Worsening
por: Levy, Marilyne, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_kmbvod0jr2gg8q8jbha0jnrsoh